Axon Enterprise, Inc. (NASDAQ:AXON) Receives $488.67 Consensus Price Target from Analysts

Shares of Axon Enterprise, Inc. (NASDAQ:AXON - Get Free Report) have earned an average rating of "Buy" from the thirteen ratings firms that are presently covering the stock, MarketBeat reports. Thirteen analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $488.67.

AXON has been the topic of several recent analyst reports. Robert W. Baird lifted their target price on Axon Enterprise from $600.00 to $800.00 and gave the company an "outperform" rating in a research note on Friday, December 6th. Northland Securities boosted their target price on shares of Axon Enterprise from $365.00 to $550.00 and gave the stock an "outperform" rating in a report on Monday, November 11th. JMP Securities raised their target price on shares of Axon Enterprise from $430.00 to $500.00 and gave the company a "market outperform" rating in a research note on Thursday, October 31st. Morgan Stanley upgraded shares of Axon Enterprise from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $500.00 to $700.00 in a report on Tuesday, December 3rd. Finally, The Goldman Sachs Group increased their price objective on shares of Axon Enterprise from $385.00 to $441.00 and gave the company a "buy" rating in a report on Wednesday, October 23rd.

Axon Enterprise Price Performance

Axon Enterprise stock traded down $10.00 during mid-day trading on Tuesday, hitting $594.32. The stock had a trading volume of 510,224 shares, compared to its average volume of 611,868. Axon Enterprise has a one year low of $241.72 and a one year high of $698.67. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $45.32 billion, a P/E ratio of 153.57, a P/E/G ratio of 14.19 and a beta of 1.01. The firm's 50 day moving average is $581.56 and its 200 day moving average is $432.69.

Insider Activity at Axon Enterprise

In other news, CEO Patrick W. Smith sold 4,767 shares of the company's stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $404.14, for a total transaction of $1,926,535.38. Following the transaction, the chief executive officer now owns 2,925,060 shares of the company's stock, valued at approximately $1,182,133,748.40. This represents a 0.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Michael Garnreiter sold 1,000 shares of the stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $437.98, for a total value of $437,980.00. Following the completion of the sale, the director now owns 26,259 shares in the company, valued at approximately $11,500,916.82. The trade was a 3.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 55,862 shares of company stock worth $32,814,021. Company insiders own 6.10% of the company's stock.

Institutional Trading of Axon Enterprise

Large investors have recently made changes to their positions in the stock. Public Sector Pension Investment Board boosted its holdings in shares of Axon Enterprise by 19.2% in the third quarter. Public Sector Pension Investment Board now owns 3,104 shares of the biotechnology company's stock valued at $1,240,000 after purchasing an additional 500 shares during the period. CIBC Asset Management Inc lifted its holdings in shares of Axon Enterprise by 9.2% in the 3rd quarter. CIBC Asset Management Inc now owns 10,578 shares of the biotechnology company's stock worth $4,227,000 after buying an additional 895 shares during the period. Foundations Investment Advisors LLC bought a new stake in shares of Axon Enterprise in the 3rd quarter valued at about $221,000. Sequoia Financial Advisors LLC lifted its position in shares of Axon Enterprise by 4.9% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 1,727 shares of the biotechnology company's stock worth $690,000 after purchasing an additional 81 shares during the period. Finally, Axxcess Wealth Management LLC bought a new position in shares of Axon Enterprise during the third quarter valued at approximately $814,000. 79.08% of the stock is owned by hedge funds and other institutional investors.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.